CNBC
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
EconomyDaily Composite
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement

